Scandion Oncology

Overcoming cancer drug resistance

Scandion Oncology ("Scandion" or the "Company") announces that the exercise period for the warrants of series TO 2, which were issued in connection with the Company's rights issues of units during the second quarter of 2024, begins today on 4 November 2024. Note that warrants of series TO 2 not sold by 14 November 2024 or used to subscribe for shares no later than on 18 November 2024, expire without value. Scandion carried out a rights issue of units during the second quarter of 2024. Within the rights issue, a total of 143,416,179 warrants of series TO 2 were issued. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 2 shall correspond to seventy (70) per cent of the volume weighted average price of the Company’s share during the period from and including 16 October 2024 up to and including 29 October 2024, however not lower than the quota value of the share and not higher than 125 per cent of the subscription price in the rights issue. During the measurement period, the volume-weighted average price for the Company's share was approximately SEK 0,12, therefore the exercise price for the warrants of series TO 2 has been determined to SEK 0,12. Subscription of shares by exercise of warrants of series TO 2 will take place during the period from and including 4 November 2024 up to and including 18 November 2024. If all the warrants of series TO 2 are exercised, the Company will receive approximately SEK 17,2 million before issue costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than on 18 November 2024 or sell the warrants no later than on 14 November 2024. Please observe that certain nominees might close their subscription earlier than on 18 November 2024. If all warrants of series TO 2 are exercised the share capital will increase with DKK 10,541,089.15650 through the issuance of 143,416,179 new shares. This correspondence to a dilution effect of approximately 38,2 per cent of the number of shares and number of votes. Full terms and conditions regarding the warrants of series TO 2 and information about the Company is available in the prospectus which was approved by the Danish Financial Supervisory Authority (the "DFSA") […]

On Wednesday 30 October 2024, Scandion Oncology issued a release mistakenly stating that the exercise price for warrants of series TO 2 would be SEK 0.11. The correct exercise price is SEK 0.12 as SEK 0.11 would result in an exercise price lower than the quota value of the share. As a result, if all the warrants of series TO 2 are exercised, the Company will receive approximately SEK 17,2 million before issue costs rather than the previously stated SEK 15,8 million. The corrected press release is provided in full below. Scandion Oncology announces exercise price for warrants of series TO 2 Scandion Oncology ("Scandion" or the "Company") announces that the exercise price for the warrants of series TO 2 has been determined to SEK 0,12 and that the exercise period starts on 4 November 2024. Scandion carried out a rights issue of units during the second quarter of 2024. Within the rights issue, a total of 143,416,179 warrants of series TO 2 were issued. One (1) warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 2 shall correspond to seventy (70) per cent of the volume weighted average price of the Company’s share during the period from and including 16 October 2024 up to and including 29 October 2024, however not lower than the quota value of the share and not higher than 125 per cent of the subscription price in the rights issue. During the measurement period, the volume-weighted average price for the Company's share was approximately SEK 0,12, therefore the exercise price for the warrants of series TO 2 has been determined to SEK 0,12. Subscription of shares by exercise of warrants of series TO 2 will take place during the period from and including 4 November 2024 up to and including 18 November 2024. If all the warrants of series TO 2 are exercised, the Company will receive approximately SEK 17,2 million before issue costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than on 18 November 2024 or sell the warrants no later than on 14 November 2024. Please observe that certain nominees might close their subscription earlier than on 18 November 2024. If all warrants of series TO 2 are exercised the share […]